D. Boral Capital analyst Jason Kolbert downgraded Scilex (SCLX) to Hold from Buy after the company announced a 1-for-35 reverse stock split, effective April 15. While the firm recognizes the ...

D. Boral Capital upgraded Citius Pharmaceuticals (CTXR) to Buy from Hold with a $9 price target. Citius owns 90% of Citius Oncology (CTOR), which is close to commercializing Lymphir, an ...